JP2014524441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524441A5 JP2014524441A5 JP2014526205A JP2014526205A JP2014524441A5 JP 2014524441 A5 JP2014524441 A5 JP 2014524441A5 JP 2014526205 A JP2014526205 A JP 2014526205A JP 2014526205 A JP2014526205 A JP 2014526205A JP 2014524441 A5 JP2014524441 A5 JP 2014524441A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 6
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 5
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 0 *(c1c(*2)cccc1)c1c2cccc1 Chemical compound *(c1c(*2)cccc1)c1c2cccc1 0.000 description 11
- VTSFLGMBTHXJSM-UHFFFAOYSA-N CN1c2ccccc2CCc2ccccc12 Chemical compound CN1c2ccccc2CCc2ccccc12 VTSFLGMBTHXJSM-UHFFFAOYSA-N 0.000 description 2
- OUBWRAWBSRYHDZ-UHFFFAOYSA-N OC(CNS([Ar])(=O)=O)CN1c2ccccc2Sc2c1cccc2 Chemical compound OC(CNS([Ar])(=O)=O)CN1c2ccccc2Sc2c1cccc2 OUBWRAWBSRYHDZ-UHFFFAOYSA-N 0.000 description 2
- GQGONHQCCHSZCE-UHFFFAOYSA-N CC(C1)=CC=CC2=C1Sc1ccccc1N2C Chemical compound CC(C1)=CC=CC2=C1Sc1ccccc1N2C GQGONHQCCHSZCE-UHFFFAOYSA-N 0.000 description 1
- FDWIBERVOGJHHG-ZGTCLIOFSA-N CN1C(C=CCC2)=C2[C@H](CC2)C2c2c1cccc2 Chemical compound CN1C(C=CCC2)=C2[C@H](CC2)C2c2c1cccc2 FDWIBERVOGJHHG-ZGTCLIOFSA-N 0.000 description 1
- HEMOWWQXBAGSHD-UHFFFAOYSA-N CN1C2=C=CC=CC=C2CCc2c1cccc2 Chemical compound CN1C2=C=CC=CC=C2CCc2c1cccc2 HEMOWWQXBAGSHD-UHFFFAOYSA-N 0.000 description 1
- QXBUYALKJGBACG-UHFFFAOYSA-N CN1c(cccc2)c2Sc2c1cccc2 Chemical compound CN1c(cccc2)c2Sc2c1cccc2 QXBUYALKJGBACG-UHFFFAOYSA-N 0.000 description 1
- JWMVTMSJLATFRN-KWCCSABGSA-N CN1c2ccccc2C(C2)[C@H]2c2c1cccc2 Chemical compound CN1c2ccccc2C(C2)[C@H]2c2c1cccc2 JWMVTMSJLATFRN-KWCCSABGSA-N 0.000 description 1
- KRPMVVDBSXOPPW-AEXHNKLYSA-N C[C@H](CCc1ccccc11)c2ccccc2/C1=C/C Chemical compound C[C@H](CCc1ccccc11)c2ccccc2/C1=C/C KRPMVVDBSXOPPW-AEXHNKLYSA-N 0.000 description 1
- YVJXPKNBXSCSRP-HBWUDVDXSA-N O=S(NC(C=C1)=CC=CC=CC2=C1c1ccccc1C(C1)[C@H]1c1ccccc21)([AlH2])=O Chemical compound O=S(NC(C=C1)=CC=CC=CC2=C1c1ccccc1C(C1)[C@H]1c1ccccc21)([AlH2])=O YVJXPKNBXSCSRP-HBWUDVDXSA-N 0.000 description 1
- ASTONNBOAHNFSK-UHFFFAOYSA-N O=S(NCN1c2ccccc2Sc2c1cccc2)([AlH2])=O Chemical compound O=S(NCN1c2ccccc2Sc2c1cccc2)([AlH2])=O ASTONNBOAHNFSK-UHFFFAOYSA-N 0.000 description 1
- CTEINOJHCYPEBL-UHFFFAOYSA-N O=S(NN(c1c(CC2)cccc1)c1c2cccc1)([AlH2])=O Chemical compound O=S(NN(c1c(CC2)cccc1)c1c2cccc1)([AlH2])=O CTEINOJHCYPEBL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523897P | 2011-08-16 | 2011-08-16 | |
| US61/523,897 | 2011-08-16 | ||
| PCT/US2012/051097 WO2013025882A2 (en) | 2011-08-16 | 2012-08-16 | Tricyclic compounds as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524441A JP2014524441A (ja) | 2014-09-22 |
| JP2014524441A5 true JP2014524441A5 (enExample) | 2016-12-01 |
| JP6105585B2 JP6105585B2 (ja) | 2017-03-29 |
Family
ID=47715694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526205A Expired - Fee Related JP6105585B2 (ja) | 2011-08-16 | 2012-08-16 | 抗腫瘍剤としての三環式化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9540358B2 (enExample) |
| EP (1) | EP2744808A4 (enExample) |
| JP (1) | JP6105585B2 (enExample) |
| KR (1) | KR20140070550A (enExample) |
| CN (1) | CN103889981B (enExample) |
| AU (2) | AU2012296528B2 (enExample) |
| BR (1) | BR112014003567A2 (enExample) |
| CA (1) | CA2844985A1 (enExample) |
| HK (1) | HK1198384A1 (enExample) |
| WO (1) | WO2013025882A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105073117A (zh) | 2013-02-19 | 2015-11-18 | 西奈山伊坎医学院 | 作为抗癌剂的三环杂环化合物 |
| CN103232447B (zh) * | 2013-04-02 | 2015-06-03 | 陕西科技大学 | 3-乙酰基-5-乙酰亚氨基-2-(n-吩噻嗪基)-1,3,4-噻二唑及其制备方法和应用 |
| CN106458916A (zh) * | 2014-03-11 | 2017-02-22 | 西奈山伊坎医学院 | 受限制的三环磺酰胺 |
| JP2017512766A (ja) * | 2014-03-11 | 2017-05-25 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド |
| WO2016008048A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
| CN104529898B (zh) * | 2015-01-15 | 2016-07-27 | 成都丽凯手性技术有限公司 | 氮杂二苯并环辛炔类化合物及其制备方法 |
| JP2018518522A (ja) | 2015-06-23 | 2018-07-12 | ケース ウエスタン リザーブ ユニバーシティ | 癌を治療するための組成物及び方法 |
| US10450282B2 (en) | 2015-08-06 | 2019-10-22 | Icahn School Of Medicine At Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
| WO2017044575A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| WO2017044571A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents |
| EP3347350A1 (en) * | 2015-09-09 | 2018-07-18 | Icahn School of Medicine at Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| WO2017044572A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Ring constrained diarylamino sulfonamides as anti-cancer agents |
| JP6955485B2 (ja) * | 2015-09-09 | 2021-10-27 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| CN111171006B (zh) * | 2020-01-29 | 2023-05-12 | 成都睿智化学研究有限公司 | 一种3-取代亚氨基二苄氨基类化合物的工艺方法 |
| WO2021188949A1 (en) * | 2020-03-20 | 2021-09-23 | Atux Iskay Llc | 3-diarylmethylenes and uses thereof |
| GB2597446A (en) | 2020-07-21 | 2022-02-02 | Demuris Ltd | Compounds and their uses |
| US20240368105A1 (en) | 2021-08-18 | 2024-11-07 | Atux Iskay Llc | 2-diarylmethyl-4-aminotetrahydropyran derivatives and related compounds as anticancer, antiinflammatory, antifibrotic and neuroprotective agents |
| CN115554303B (zh) * | 2021-09-18 | 2024-07-09 | 上海科技大学 | 一种三环类化合物、其制备方法及其应用 |
| EP4673135A1 (en) * | 2023-02-27 | 2026-01-07 | Atux Iskay LLC | N,n'-sulfonimidamides as anticancer, antiinflammatory, antifibrotic and neuroprotective agents |
| CN118026942B (zh) * | 2024-04-11 | 2024-06-28 | 江西师范大学 | 11-碘-二苯并[b,e][1,4]二氮杂卓化合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK88606C (da) | 1958-05-09 | 1960-02-29 | Kefalas As | Fremgangsmåde til fremstilling af i 9-stillingen substituerede thiaxantener eller deres syreadditionssalte. |
| GB8510680D0 (en) | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| WO1995003279A1 (en) | 1993-07-26 | 1995-02-02 | Eisai Co., Ltd. | Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring |
| GB9703992D0 (en) | 1997-02-26 | 1997-04-16 | Rolabo Sl | Process |
| US6903102B2 (en) | 2001-09-06 | 2005-06-07 | Schering Corporation | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| EP1481673A4 (en) * | 2002-02-05 | 2008-09-24 | Ajinomoto Kk | MEDICAL COMPOSITIONS WITH GABAPENTIN OR PREGABALINE AND N-TYPE CALCIUM CHANNEL ANTAGONIST |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| KR20070092297A (ko) * | 2004-12-21 | 2007-09-12 | 데브젠 엔브이 | Ｋｖ4 이온 채널 활성을 갖는 화합물 |
| CN101277949A (zh) | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| WO2008121859A1 (en) * | 2007-03-30 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
-
2012
- 2012-08-16 JP JP2014526205A patent/JP6105585B2/ja not_active Expired - Fee Related
- 2012-08-16 CN CN201280050818.3A patent/CN103889981B/zh not_active Expired - Fee Related
- 2012-08-16 AU AU2012296528A patent/AU2012296528B2/en not_active Ceased
- 2012-08-16 HK HK14111891.1A patent/HK1198384A1/xx unknown
- 2012-08-16 CA CA2844985A patent/CA2844985A1/en not_active Abandoned
- 2012-08-16 KR KR1020147006897A patent/KR20140070550A/ko not_active Ceased
- 2012-08-16 EP EP12823881.3A patent/EP2744808A4/en not_active Withdrawn
- 2012-08-16 US US14/238,511 patent/US9540358B2/en active Active
- 2012-08-16 WO PCT/US2012/051097 patent/WO2013025882A2/en not_active Ceased
- 2012-08-16 BR BR112014003567A patent/BR112014003567A2/pt not_active Application Discontinuation
-
2017
- 2017-10-05 AU AU2017239562A patent/AU2017239562A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543967A5 (enExample) | ||
| JP2023518286A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| RU2014135401A (ru) | Производные пиридона | |
| JP2015523383A5 (enExample) | ||
| JP2010504286A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| JP2011526917A5 (enExample) | ||
| JP2017531041A5 (enExample) | ||
| CA2545942A1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| ME02125B (me) | Inhibitori protein apoptoze (iap) | |
| JP2012523457A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2016508521A5 (enExample) | ||
| JP2013502441A5 (enExample) | ||
| JP2018526419A5 (enExample) | ||
| JP2018526416A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2011506402A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2021500335A5 (enExample) | ||
| JP2017506248A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |